Literature DB >> 9756794

In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries.

J Gieffers1, W Solbach, M Maass.   

Abstract

Chlamydia pneumoniae strains have been recovered from arteriosclerotic coronary arteries, but their antibiotic susceptibility profiles have not yet been examined. We report in vitro susceptibility data for five cardiovascular C. pneumoniae isolates. These strains did not differ significantly from respiratory strains in their patterns of susceptibility to azithromycin, erythromycin, roxithromycin, ofloxacin, doxycycline, rifampin, and penicillin G. Roxithromycin was the most active macrolide, and rifampin was the most effective drug overall.

Entities:  

Mesh：

Year:  1998        PMID： 9756794      PMCID： PMC105936     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Infections caused by Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

2.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

Authors:  P Saikku; M Leinonen; K Mattila; M R Ekman; M S Nieminen; P H Mäkelä; J K Huttunen; V Valtonen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

3.  In vitro drug susceptibility of Chlamydia sp. strain TWAR.

Authors:  C C Kuo; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

4.  Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group.

Authors:  J A Ramirez
Journal:  Ann Intern Med       Date:  1996-12-15       Impact factor: 25.391

Review 5.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  Evaluation of culture conditions used for isolation of Chlamydia pneumoniae.

Authors:  M Maass; U Harig
Journal:  Am J Clin Pathol       Date:  1995-02       Impact factor: 2.493

7.  Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease.

Authors:  M Maass; C Bartels; P M Engel; U Mamat; H H Sievers
Journal:  J Am Coll Cardiol       Date:  1998-03-15       Impact factor: 24.094

8.  In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.

Authors:  R B Jones; G L Ridgway; S Boulding; K L Hunley
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

9.  Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old).

Authors:  C C Kuo; J T Grayston; L A Campbell; Y A Goo; R W Wissler; E P Benditt
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

10.  Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues.

Authors:  L A Campbell; E R O'Brien; A L Cappuccio; C C Kuo; S P Wang; D Stewart; D L Patton; P K Cummings; J T Grayston
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226
View more
  7 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Culture-negative endocarditis due to Chlamydia pneumoniae.

Authors:  R Gdoura; S Pereyre; I Frikha; N Hammami; M Clerc; Y Sahnoun; C Bebear; M Daoud; B de Barbeyrac; A Hammami
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

3.  Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.

Authors:  Jan Rupp; Andreas Gebert; Werner Solbach; Matthias Maass
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial.

Authors:  U Burkhardt; R Zahn; U Höffler; K E Siegler; B Frilling; M Weber; M Gottwik; M Wehr; F Seidel; S Rosocha; U Tebbe; J Senges
Journal:  Z Kardiol       Date:  2004-09

6.  Chlamydia pneumoniae induces aponecrosis in human aortic smooth muscle cells.

Authors:  Claudia Dumrese; Christine F Maurus; Daniel Gygi; Mårten K J Schneider; Michael Walch; Peter Groscurth; Urs Ziegler
Journal:  BMC Microbiol       Date:  2005-01-21       Impact factor: 3.605

7.  The Genetic Transformation of Chlamydia pneumoniae.

Authors:  Ian N Clarke; Jan Rupp; Kensuke Shima; Maximilian Wanker; Rachel J Skilton; Lesley T Cutcliffe; Christiane Schnee; Thomas A Kohl; Stefan Niemann; Javier Geijo; Matthias Klinger; Peter Timms; Thomas Rattei; Konrad Sachse
Journal:  mSphere       Date:  2018-10-10       Impact factor: 4.389
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.